The dramatic rise in oropharyngeal squamous cell carcinoma associated with the human papilloma virus (HPV) has brought significant change to the interaction between patients and head and neck oncologists. HPV-induced cancers are generally the result of elements from the patient’s sexual history, and otolaryngologists are generally less experienced than primary care physicians in addressing patient questions relating to sexual history and practices. This article addresses questions commonly posed by patients relating to HPV-induced head and neck cancers, issues related to HPV vaccination, and surveillance of HPV-related lesions. Supporting data are provided such that physicians may be better equipped to sufficiently address patient queries on this topic.
Data Sources
Available peer-reviewed literature and clinical practice guidelines.
Review Methods
Assessment and discussion of specific topics by authors selected from the Head and Neck Surgery Education Committee of the American Academy of Otolaryngology—Head and Neck Surgery Foundation.
Results
An educational “miniseminar” resulted in a notable increase in attendee knowledge and comfort regarding oropharyngeal squamous cell carcinoma counseling for patients in the setting of HPV-positive disease.
Conclusions and Implications for Practice
The dramatic increase in HPV-associated head and neck cancers has resulted in a changed paradigm of the physician-patient interaction. Care providers in today’s environment must be prepared to counsel patients regarding sexually transmitted diseases and high-risk sexual behaviors. Examination of the existing data provides the foundation with which to construct a framework in which physicians can effectively communicate information and recommendations as they pertain to HPV-related carcinoma.
ChaturvediAKEngelsEAPfeifferRM. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301.
2.
D’SouzaGKreimerARViscidiR. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
3.
LuryiALYarbroughWGNiccolaiLM. Public awareness of head and neck cancers: a cross-sectional survey. JAMA Otolaryngol Head Neck Surg. 2014;140:639-646.
4.
BaxiSSShumanAGCornerGW. Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know. Head Neck. 2013;35:1534-1541.
5.
VerhoevenVBaayMFBaayPELardonFVan RoyenPVermorkenJB.Everything you always wanted to know about HPV (but could not ask your doctor). Patient Educ Couns. 2010;81:101-105.
6.
ShumanAGWolfGT.Human papillomavirus status in head and neck cancer: the ethics of disclosure. Cancer. 2010;116:4221-4226.
7.
SatterwhiteCLTorroneEMeitesE. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-193.
8.
Centers for Disease Control and Prevention. Human papillomavirus (HPV). http://www.cdc.gov/hpv. Accessed April 15, 2015.
9.
PickardRKXiaoWBroutianTRHeXGillisonML.The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis. 2012;39:559-566.
10.
GillisonMLBroutianTPickardRK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
11.
GiulianoARNyitrayAGKreimerAR. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136:2752-2760.
12.
BlitzerGCSmithMAHarrisSLKimpleRJ.Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2014;88:761-770.
GillisonMLD’SouzaGWestraW. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420.
15.
PytyniaKBDahlstromKRSturgisEM.Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50:380-386.
16.
GeeJNalewayAShuiI. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279-8284.
17.
Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705-1708.
18.
MarkowitzLEDunneEFSaraiyaMLawsonHWChessonHUngerER.Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-24.
19.
VillaLLCostaRLPettaCA. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
20.
MarkowitzLEHaririSLinC. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208:385-393.
21.
HerreroRQuintWHildesheimA. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8:e68329.
22.
Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years: United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117-1123.
23.
Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years: United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:685-693.
GourinCGWilliamsHTSeaboltWNHerdmanAVHowingtonJWTerrisDJ.Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope. 2006;116:705-710.
26.
ZhangIBranstetterBFTBeswickDMMaxwellJHGoodingWEFerrisRL.The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2011;137:1106-1111.
27.
CrandleyEWilsonDSimA. Patterns of distant failure and second primary cancers in patients with oropharyngeal squamous cell carcinoma: implications for surveillance methodology. J Can Res Updates. 2014;3:151-161.
28.
YarbroughWGSlebosRJLieblerD.Proteomics: clinical applications for head and neck squamous cell carcinoma. Head Neck. 2006;28:549-558.
29.
AhnSMChanJYZhangZ. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:846-854.
30.
LaskarisG.Color Atlas of Oral Diseases. 3rd ed.New York, NY: Thieme; 2003.
31.
NevilleBDammDAllenC. Oral Pathology. St Louis, MO: Saunders Elsevier; 2009.
32.
PringleGA.The role of human papillomavirus in oral disease. Dent Clin North Am. 2014;58:385-399.
33.
HuangLWSeowKM.Oral sex is a risk factor for human papillomavirus-associated nasopharyngeal carcinoma in husbands of women with cervical cancer. Gynecol Obstet Invest. 2010;70:73-75.
34.
HemminkiKDongC.Cancer in husbands of cervical cancer patients. Epidemiology. 2000;11:347-349.
35.
HemminkiKDongCFrischM.Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev. 2000;9:433-437.
36.
KreimerARPierce CampbellCMLinHY. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382:877-887.
37.
D’SouzaGGrossNDPaiSI. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014;32:2408-2415.
38.
LorenzonLTerrenatoIDonaMG. Prevalence of HPV infection among clinically healthy Italian males and genotype concordance between stable sexual partners. J Clin Virol. 2014;60:264-269.
39.
ReiterPLPendergraftWF3rdBrewerNT.Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev. 2010;19:2916-2931.
40.
RintalaMGrenmanSPuranenMSyrjanenS.Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol. 2006;35:89-94.
41.
CoutleeFTrottierAMGhattasG. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis. 1997;24:23-31.
42.
KreimerARJohanssonMWaterboerT. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31:2708-2715.
43.
RietbergenMMBraakhuisBJMoukhtariN. No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors. J Oral Pathol Med. 2014;43:137-142.
44.
ThavarajSStokesAMazunoK. Patients with HPV-related tonsil squamous cell carcinoma rarely harbour oncogenic HPV infection at other pharyngeal sites. Oral Oncol. 2014;50:241-246.
45.
PeckBWDahlstromKRGanSJ. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck. 2013;35:794-799.
46.
XuCCBironVLPuttaguntaLSeikalyH.HPV status and second primary tumours in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2013;42:36.
47.
Hocevar-BoltezarIMaticicMSereg-BaharM. Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271:3255-3262.
